# Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124

> **NCT04176653** · PHASE1 · WITHDRAWN · sponsor: **Silence Therapeutics plc**

## Conditions studied

- Non-transfusion-dependent Thalassemia
- Low Risk Myelodysplastic Syndrome

## Interventions

- **DRUG:** SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo

## Key facts

- **NCT ID:** NCT04176653
- **Lead sponsor:** Silence Therapeutics plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-08-20
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-10-14
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study stopped prior to subject administered first dose, due to COVID-19
- **Last updated:** 2020-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04176653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04176653, "Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04176653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*